Lixian Wu

922 total citations
42 papers, 619 citations indexed

About

Lixian Wu is a scholar working on Molecular Biology, Oncology and Hematology. According to data from OpenAlex, Lixian Wu has authored 42 papers receiving a total of 619 indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Molecular Biology, 11 papers in Oncology and 7 papers in Hematology. Recurrent topics in Lixian Wu's work include PARP inhibition in cancer therapy (8 papers), Chronic Myeloid Leukemia Treatments (6 papers) and DNA Repair Mechanisms (5 papers). Lixian Wu is often cited by papers focused on PARP inhibition in cancer therapy (8 papers), Chronic Myeloid Leukemia Treatments (6 papers) and DNA Repair Mechanisms (5 papers). Lixian Wu collaborates with scholars based in China, United States and Hong Kong. Lixian Wu's co-authors include Jianhua Xu, Lingyu Zhang, Dali Zheng, Youguang Lu, Xingyong Chen, Yuanzhong Chen, Shanshan Lin, Yang Liu, Wenshu Chen and Yuanzhong Chen and has published in prestigious journals such as Blood, PLoS ONE and Clinical Cancer Research.

In The Last Decade

Lixian Wu

40 papers receiving 612 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Lixian Wu China 16 350 141 86 66 58 42 619
Mohammed Sikander United States 12 347 1.0× 133 0.9× 90 1.0× 141 2.1× 35 0.6× 23 562
Lehe Yang China 18 396 1.1× 275 2.0× 124 1.4× 134 2.0× 104 1.8× 42 878
Hongjiang Xu China 15 373 1.1× 106 0.8× 43 0.5× 27 0.4× 26 0.4× 41 773
Hareesh B. Nair United States 15 259 0.7× 224 1.6× 47 0.5× 80 1.2× 43 0.7× 48 800
Yanan Jiang China 15 353 1.0× 183 1.3× 37 0.4× 112 1.7× 50 0.9× 58 659
Samil Jung South Korea 17 497 1.4× 88 0.6× 33 0.4× 83 1.3× 46 0.8× 34 877
Zhaoshi Bai China 15 310 0.9× 120 0.9× 21 0.2× 47 0.7× 43 0.7× 30 818
Wenjing Chen China 17 665 1.9× 103 0.7× 55 0.6× 114 1.7× 39 0.7× 64 1.0k
Yanni Ma China 18 339 1.0× 112 0.8× 30 0.3× 60 0.9× 24 0.4× 50 761

Countries citing papers authored by Lixian Wu

Since Specialization
Citations

This map shows the geographic impact of Lixian Wu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lixian Wu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lixian Wu more than expected).

Fields of papers citing papers by Lixian Wu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lixian Wu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lixian Wu. The network helps show where Lixian Wu may publish in the future.

Co-authorship network of co-authors of Lixian Wu

This figure shows the co-authorship network connecting the top 25 collaborators of Lixian Wu. A scholar is included among the top collaborators of Lixian Wu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lixian Wu. Lixian Wu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Xu, Yingying, Yang Liu, Chengyan Wang, et al.. (2024). Ferroptosis boosted oral cancer photodynamic therapy by carrier-free Sorafenib-Ce6 self-assembly nanoparticles. Journal of Controlled Release. 366. 798–811. 34 indexed citations
3.
Wu, Lixian, et al.. (2023). Investigation of biological activity of Alpinia platychilus extracts and its use as a natural preservative in fruits. Journal of Food Measurement & Characterization. 18(3). 1705–1721. 3 indexed citations
4.
Liu, Yafang, Shuang Liu, Dandan Jiang, et al.. (2023). Analysis of complete mitogenomes and phylogenetic relationships of Frontopsylla spadix and Neopsylla specialis. Frontiers in Veterinary Science. 10. 4 indexed citations
5.
Sun, Long, et al.. (2022). Lack of geographical and ethnic distribution of Hepatitis B virus genotypes in Hainan Island, China. Infection Genetics and Evolution. 107. 105401–105401. 2 indexed citations
6.
Li, Ge, Shanshan Lin, Xinhua Wu, et al.. (2022). A PARP1 PROTAC as a novel strategy against PARP inhibitor resistance via promotion of ferroptosis in p53-positive breast cancer. Biochemical Pharmacology. 206. 115329–115329. 43 indexed citations
7.
Wang, Xue, et al.. (2022). Cyclocytidine hydrochloride inhibits the synthesis of relaxed circular DNA of hepatitis B virus. PeerJ. 10. e13719–e13719. 7 indexed citations
8.
Lin, Shanshan, et al.. (2022). Synthesis of novel dual target inhibitors of PARP and EGFR and their antitumor activities in triple negative breast cancers. Bioorganic & Medicinal Chemistry. 61. 116739–116739. 15 indexed citations
9.
Lin, Shanshan, Lingyu Zhang, Jingwen Liu, et al.. (2022). Discovery of CN0 as a novel proteolysis-targeting chimera (PROTAC) degrader of PARP1 that can activate the cGAS/STING immunity pathway combined with daunorubicin. Bioorganic & Medicinal Chemistry. 70. 116912–116912. 15 indexed citations
10.
Hu, Yan, Jingwen Liu, Shanshan Lin, et al.. (2021). Discovery of BP3 as an efficacious proteolysis targeting chimera (PROTAC) degrader of HSP90 for treating breast cancer. European Journal of Medicinal Chemistry. 228. 114013–114013. 26 indexed citations
11.
Zhang, Lingyu, Wenshu Chen, Xingyong Chen, et al.. (2020). Enhanced Chemotherapeutic Efficacy of PLGA-Encapsulated Epigallocatechin Gallate (EGCG) Against Human Lung Cancer. International Journal of Nanomedicine. Volume 15. 4417–4429. 68 indexed citations
12.
Ding, Li, et al.. (2020). The role of the novel LincRNA uc002jit.1 in NF-kB-mediated DNA damage repair in acute myeloid leukemia cells. Experimental Cell Research. 391(2). 111985–111985. 4 indexed citations
13.
Zhang, Lingyu, Rui-Huan Gan, Xingyong Chen, et al.. (2019). Synergistic inhibition of lung cancer cells by EGCG and NF-κB inhibitor BAY11-7082. Journal of Cancer. 10(26). 6543–6556. 49 indexed citations
14.
Wu, Lixian, et al.. (2018). The prevalence and distribution of Burkholderia pseudomallei in rice paddy within Hainan, China. Acta Tropica. 187. 165–168. 17 indexed citations
15.
Zhang, Nanwen, et al.. (2015). A novel synthetic novobiocin analog, FM-Nov17, induces DNA damage in CML cells through generation of reactive oxygen species. Pharmacological Reports. 68(2). 423–428. 3 indexed citations
16.
Wu, Lixian, Yang Liu, Liguang Lou, et al.. (2014). Dual Inhibition of Bcr-Abl and Hsp90 by C086 Potently Inhibits the Proliferation of Imatinib-Resistant CML Cells. Clinical Cancer Research. 21(4). 833–843. 39 indexed citations
17.
Wu, Lixian, Ningfei An, Junru Wang, et al.. (2011). IKKβ Regulates the Repair of DNA Double-Strand Breaks Induced by Ionizing Radiation in MCF-7 Breast Cancer Cells. PLoS ONE. 6(4). e18447–e18447. 28 indexed citations
18.
Xu, Jianhua, et al.. (2007). Curcumin synergistically augments bcr/abl phosphorothioate antisense oligonucleotides to inhibit growth of chronic myelogenous leukemia cells. Acta Pharmacologica Sinica. 28(1). 105–110. 16 indexed citations
19.
Xu, Jianhua, et al.. (2007). Curcumin synergistically augments bcr/abl phosphorothioate antisense oligonucleotides to inhibit growth of chronic myelogenous leukemia cells. Acta Pharmacologica Sinica. 28(1). 105–110. 2 indexed citations
20.
Wu, Lixian, et al.. (2006). Down-regulation of p210bcr/abl by curcumin involves disrupting molecular chaperone functions of Hsp901. Acta Pharmacologica Sinica. 27(6). 694–699. 29 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Mohammed Sikander Breakdown of academic impact, for papers by Lehe Yang Breakdown of academic impact, for papers by Hongjiang Xu Breakdown of academic impact, for papers by Hareesh B. Nair Breakdown of academic impact, for papers by Yanan Jiang Breakdown of academic impact, for papers by Samil Jung Breakdown of academic impact, for papers by Zhaoshi Bai Breakdown of academic impact, for papers by Wenjing Chen Breakdown of academic impact, for papers by Yanni Ma
Rankless by CCL
2026